Mercados españoles abiertos en 33 mins
  • Reuters

    Swiss pharma firm Relief, U.S. partner fight after hopes dented for COVID-19 drug

    A Swiss company whose market capitalization rose at one time to more than 1.5 billion Swiss francs ($1.6 billion) on hopes an old drug it owned would succeed against COVID-19 is embroiled in a dispute with its U.S. partner, it said in a statement. Relief Therapeutics' market cap has fallen about 70% from a high in the third quarter of 2020, as the company's aviptadil, a 50-year-old medicine, failed to win U.S. emergency approval and in February demonstrated no survival benefit at 28 days in a U.S. clinical trial of people with COVID-19 respiratory failure. Relief said on Monday that its U.S. partner, NeuroRx, and it are fighting over issues including sharing of trial data, invoices totaling about $4 million that NeuroRx contends Relief must pay, funding for clinical trials, the allocation of potential profits, and other issues.

  • E.SUN FHC Commits to "Business Ambition for 1.5°C"
    Business Wire

    E.SUN FHC Commits to "Business Ambition for 1.5°C"

    E.SUN FHC signed the "Business Ambition for 1.5°C" pledge this year with intermediate targets approved by the Science-Based Targets initiative (SBTi). E.SUN is the first financial institution in Asia to adopt the 1.5°C climate target, an initiative aligned with international standards. The company has set mid- and long-term goals and announced before Earth Day that all of E.SUN’s domestic proprietary buildings will be converted into green buildings by 2027. 100% renewable energy will be used at domestic business locations by 2030. The bank will net-zero carbon by 2050. Through planned, systematic, and disciplined actions, concrete measures will be taken and the greatest efforts will be made on the part of E.SUN to control the effects of global warming.

  • Explainer: What's next for Jack Ma's Ant Group after China orders revamp?

    Explainer: What's next for Jack Ma's Ant Group after China orders revamp?

    China has imposed a sweeping restructuring plan on Jack Ma's Ant Group, the fintech conglomerate whose record $37 billion IPO was derailed by regulators in November, that will see the group become a financial holdings company among other things. Ant, valued at around $315 billion at its IPO pricing, is also exploring options for founder Ma to divest his stake and give up control, as meetings with regulators signalled the move could help draw a line under Beijing's scrutiny of its business, Reuters exclusively reported on Saturday. Brokerage Jefferies estimated in a report last week that Ant will need 13.4-20.1 billion yuan ($2-$3 billion) of capital to meet the minimum capital adequacy ratio for consumer finance companies.